Tuesday, 15th February, 2022. 3pm EST/ 8pm UK/ 9pm CET
Dr. Thomas (Rusty) Pool and Prof. Barry Behr with Richard Banks
Introduction TJ Farnsworth Founder and CEO Inception Fertility This talk is sponsored by Inception Fertility
“The Business of Operating Multiple ART laboratories” Dr Kathy Miller, Vice President of MedTech For Solutions This talk is sponsored by MedTech For Solutions
Supply and Demand: The Life of Per Diem/Locum Embryologists Video and Discussion
Mr. Farnsworth is the CEO and Founder of Inception Fertility.
Mr. Farnsworth and his wife welcomed a baby after a two-year infertility journey, however the process left them frustrated. As a serial entrepreneur, Mr. Farnsworth recognized an opportunity to reshape the industry and improve the patient experience, and he launched Inception in 2014.
Today, Inception is the largest provider of comprehensive fertility clinics and services in North America and one that bridges together the latest science and technologies with a commitment to enhancing the patient experience.
Inception’s family of brands include The Prelude Network™ , the largest provider of comprehensive fertility services in the US; MyEggBank®, one of the largest donor egg banks in North America, and Bundl Fertility™ (Bundl), a multi-cycle fertility service bundling program. Prior to Inception, Mr. Farnsworth founded SightLine Health in 2005, one of the largest providers of radiation oncology services in the US, with clinical operations in California, Colorado, Kansas, Texas, and Washington. For five consecutive years, SightLine Health was listed on the Inc. 500 list of fastest-growing private companies in the US. In 2010, it was named the fastest-growing company in Houston by the Houston Business Journal and the fourth fastest-growing healthcare company in the US by Inc. Magazine.
In addition to his active role as Founder and CEO of Inception, Mr. Farnsworth sits on the board of directors of CureDuchenne, a non-profit dedicated to finding a cure for Duchenne muscular dystrophy. In 2011, Mr. Farnsworth was named one of Houston’s 40 under 40 and was awarded the 2014 Ernst & Young Entrepreneur of the Year for Healthcare award.
The author of more than 100 abstracts, papers and chapters on fertility and ART. Dr. Miller is known for research advances in the field of blastocyst culture, PGT and AI as well as a leading expert in laboratory management, QI programs, and single embryo transfer. Since 2014, she has been the managing editor of the IFFS Surveillance initiated in 1998 by Drs. Howard Jones, Jr. and Jean Cohen, assessing practices of ART at the global level.
Dr. Miller is also the Vice President of MedTech For Solutions and leads the laboratory team specializing in the implementation of cutting edge ART technologies, laboratory management and state of the art laboratory design and build out. In 2017, Dr. Miller created the OvaTools Training Institute in Fort Lauderdale. The Institute provides academic and theoretical knowledge in ART and genetics with hands-on technical training in a focused and supervised learning environment at the ART training facility.
Ellen Marello TS, Herman Rodriguez MS,TS, EA (ACE) Dani Smale MS Ashley Wong MS, TS Staci Lyn Wyatt BS
Group Chief Strategy Officer and Managing Director, Europe. A Senior Executive at ASX-listed Virtus Health since 2017, Richard Banks originally began his healthcare management career with UK NHS Graduate Management Training Scheme. Having undertaken several roles in the NHS, he moved to private hospital management with BMI Healthcare in 2009 where he was responsible for a broad portfolio of outpatient and diagnostic services including fertility. Richard then spent some time with management consultancy firms where he honed is project management and analytical skills before becoming an independent consultant for four years. During this period he undertook several key projects with a number of clients including a management restructure at Virgin Care, a financial turnaround for a major directorate at a large NHS community organization, and a transformation project at the Solicitors Regulation Authority. Whilst with Virtus Health, Richard has been central to the company’s expansion in Europe outside of their Australian heartland. He has also been responsible for developing European strategy and works in conjunction with the Virtus Senior Executive Team in shaping global strategy.
PROFESSOR BARRY R. BEHR
Professor Behr graduated from University of Nevada-Reno with honors and earned his Ph.D. with emphasis in Reproductive Physiology in 1991, board certified as High Complexity Laboratory Director in 1994. Dr Behr was the first non MD President of the Pacific Coast Reproductive Society and has been appointed as program chairman of several professional meetings. Dr. Behr was the former President of the American Association for Bioanalysts for 2015-2016. He is the director of the IVF/ART laboratory at Stanford University and is the Faculty Advisor for the Transgenic, Knockout and Tumor Model Center. In the 90’s Dr. Behr developed a culture medium for embryo culture to the blastocyst stage, which has improved pregnancy rates, implantation rates and reduced the risks of multiple gestation in IVF. He was also the co-inventor of an embryo selection technology that was featured in Time Magazine's Best of Everything as 8th place in the top 10 Medical Breakthroughs of 2010. Dr. Behr has been widely recognized for his research nationally and internationally. He has published over 200 peer-reviewed publications and book chapters
DR. THOMAS POOL
Thomas B. (Rusty) Pool, Ph.D., HCLD(ABB) is the Scientific Director of the Fertility Center of San Antonio, San Antonio, Texas, USA, a position he has held for 34 years. Prior to this, he was an Associate Professor of Cellular and Structural Biology at the University of Texas Medical School in San Antonio where he worked on culture and cryobiology of non-human primate embryos. He is board member of the Pacific Coast Fertility Society and serves on the editorial boards of Fertility and Sterility and the Journal of Assisted Reproduction and Genetics. His research interests have centered upon the physiology of the preimplantation human embryo and improvements to embryo culture technology.